Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Resignation of Ms. Inna Martin from her positions as Director, Chief Operating Officer and President

On June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx. ("we", "us", "our", "Revium" or the "Company") and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin's resignation was in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors.

In connection with Ms. Martin's departure, the Company's subsidiary, Revium Rx Ltd. ("Revium Ltd.") and Ms. Martin entered into a Termination Agreement and Waiver (the "Separation Agreement"), effective as of June 16, 2026, pursuant to which Ms. Martin's employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. Additionally, the exercise period for Ms. Martin's vested stock options to purchase up to 2,440,000 shares of the Company's common stock has been extended until September 30, 2028. Ms. Martin's shares and options are subject to certain sale restrictions as contained in the Separation Agreement.